Leqembi offers hope for Alzheimer’s patients, but access to treatment remains difficult
The new Alzheimer's drug Leqembi is being hailed as a significant advance in the fight against this debilitating disease, promising to extend the quality of life for those affected. However, patients face significant barriers to accessing this promising treatment. Leqembi, developed by Biogen and Eisai, is designed to slow the progression of Alzheimer’s by targeting and reducing beta-amyloid plaques in the brain, which are thought to play a critical role in the development of the disease. This innovative approach offers not only hope, but also additional time for patients and their families to create precious memories. Despite its potential, the…